Search - tctmd.com

Displaying 1 - 20 of 28

Sort: Relevancy | Date

News Daily News

AHA/ACC and Others Issue PAD Guideline Update With Focus on Collaborative Care

L.A. McKeown

May 17, 2024

News Daily News

New AHA/ACC Performance and Quality Metrics for Coronary Revascularization

Michael O'Riordan

July 28, 2023

News Daily News

Acute MI Patients Without Standard CVD Risk Factors at Higher Risk of Death

Michael O'Riordan

July 07, 2023

News Daily News

AHA Scientific Statement Addresses Health Disparities in PAD

L.A. McKeown

June 23, 2023

News Daily News

Many ESC Guideline Recommendations Out of Reach in Poorer Regions

Michael O'Riordan

November 29, 2022

News Daily News

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

Caitlin E. Cox

January 10, 2022

News Daily News

Diabetes Duration and Meds Don’t Impact Ticagrelor Effects in THEMIS

Todd Neale

May 14, 2021

News Daily News

Rosuvastatin-Canagliflozin Combo May Be Toxic, Case Suggests

Todd Neale

August 03, 2020

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

News Daily News

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

Yael L. Maxwell

December 20, 2019

News Daily News

To Cut CV Risk in Diabetes, Prescribe the Right Meds and Push for Lifestyle Changes

Michael O'Riordan

April 17, 2018

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Daily News

AHA Scientific Statement Highlights Sex Disparities in CV Risk Among Diabetic Patients

L.A. McKeown

December 09, 2015

News Daily News

Un Comunicado Científico de AHA Pone de Manifiesto las Disparidades de Género en el Riesgo CV de Pacientes Diabéticos

L.A. McKeown

December 09, 2015

News Daily News

Registry Study Suggests Absorb BVS Matches DES in Diabetic All-Comers

August 27, 2015

News Daily News

Un Estudio de Registro Sugiere que AVB y SLF son Iguales en Pacientes Diabéticos No Seleccionados

August 27, 2015

News Daily News

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

Yael L. Maxwell

August 12, 2015

News Daily News

BARI 2D: El Mayor Control de los Factores de Riesgo en Pacientes con Diabetes Tipo 2 Mejora Supervivencia

Yael L. Maxwell

August 12, 2015

News Daily News

Vorapaxar Effective for Secondary Prevention in Diabetic Patients With Prior MI

L.A. McKeown

February 22, 2015

News Daily News

Vorapaxar es Eficaz como Prevención Secundaria en Pacientes Diabéticos con Antecedentes de IM

L.A. McKeown

February 22, 2015

Advertisement

AHA/ACC and Others Issue PAD Guideline Update With Focus on Collaborative Care

New AHA/ACC Performance and Quality Metrics for Coronary Revascularization

Acute MI Patients Without Standard CVD Risk Factors at Higher Risk of Death

AHA Scientific Statement Addresses Health Disparities in PAD

Many ESC Guideline Recommendations Out of Reach in Poorer Regions

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

Diabetes Duration and Meds Don’t Impact Ticagrelor Effects in THEMIS

Rosuvastatin-Canagliflozin Combo May Be Toxic, Case Suggests

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

To Cut CV Risk in Diabetes, Prescribe the Right Meds and Push for Lifestyle Changes

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

AHA Scientific Statement Highlights Sex Disparities in CV Risk Among Diabetic Patients

Un Comunicado Científico de AHA Pone de Manifiesto las Disparidades de Género en el Riesgo CV de Pacientes Diabéticos

Registry Study Suggests Absorb BVS Matches DES in Diabetic All-Comers

Un Estudio de Registro Sugiere que AVB y SLF son Iguales en Pacientes Diabéticos No Seleccionados

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

BARI 2D: El Mayor Control de los Factores de Riesgo en Pacientes con Diabetes Tipo 2 Mejora Supervivencia

Vorapaxar Effective for Secondary Prevention in Diabetic Patients With Prior MI

Vorapaxar es Eficaz como Prevención Secundaria en Pacientes Diabéticos con Antecedentes de IM

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content